Mini Review

Precancerous Lesions in the Large Intestine of Rodents

Hideki Mori1 and Yasuhiro Yamada1

1Department of Pathology, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu 500–8705, Japan

Abstract: As precancerous lesions for large bowel cancers, early appearing lesions like aberrant crypt foci (ACF) are recognized. Recently, we identified β-catenin accumulated crypts (BCAC) in the colonic mucosa of rats given a colon carcinogen. BCAC have frequent β-catenin gene mutations and their pathological features are different from those of ACF. Further comparative studies on the molecular pathology and biology of both lesions, gave rise to evidences that BCAC are probably the direct precursor for the large intestinal cancers in rodents. The newly identified lesions are suggested to be a reliable biomarker for the risk assessment of environmental chemicals and for the screening of cancer preventing agents. (J Toxicol Pathol 2002; 15: 129–132)

Key words: large bowel cancer, early appearing lesions, aberrant crypt foci, β-catenin-accumulated crypts, rodent

Introduction

The concept of precancerous lesions is going to be clear in certain organs of experimental animals as well as humans. Enzyme-altered liver cell foci that appear in the process of rodent hepatocarcinogenesis is an example. Aberrant crypt foci (ACF) (Fig. 1) were first described by Bird in methylene blue-stained whole-mount preparations, of colon in animals treated with colon-specific carcinogens 1,2. Numerous studies including molecular analysis have focused on the significance of ACF as early events in colon carcinogenesis, and the lesions are now regarded as putative precancerous lesions for colorectal cancers 3,4. Similar lesions have been also identified in human colonic mucosa 5. ACF are now used as one of useful biomarkers for evaluation of potential chemopreventive agents 6. It is reported that number of crypts / focus of ACF increases with time after the carcinogen treatment, and that ACF have an increased proliferative activity 7,8. Nevertheless, there are evidences that document lack of correlation between tumor development and expression of ACF. Furthermore, it is also known that several compounds with potency to prevent the occurrence of ACF, e.g., 2-(carboxyphenyl)retinamide or genistein, enhance the development of colon cancers 9,10. Thus, it must be said that precancerous nature of ACF in the colon carcinogenesis still remains inconclusive. Recently, the authors identified β-catenin-accumulated crypts (BCAC) in the initial stage of colon carcinogenesis in rats 11,12. The lesions have a number of different pathological properties from those of ACF, suggesting that BCAC are a direct precursor lesion for colorectal neoplasms 11,12. Presently, the authors review of precancerous lesions for large intestinal cancers in rodents with emphasis on such newly identified lesions.

Pathology and Molecular Biology of BCAC

BCAC are recognized by analysis in en face preparations and in serial sections after the observation in whole-mount preparations of the colonic mucosa 11 (Fig. 1). The number of the crypts / lesion and histological abnormality of BCAC significantly increase with time course in a manner not like that of ACF. Cell proliferative activity of BCAC is higher than of ACF 12. Interestingly, BCAC are frequently accompanied by Paneth cells. It is true that Paneth cells are rather frequently recognized in colonic tumors although they are rarely seen in normal colonic epithelium. Therefore, it is suggested that the participation of Paneth cells in BCAC indicates a dis-differentiating potential of such “dysplatic” crypts. It has been reported that putative preneoplastic lesions of rat colon cancers have decreased hexosaminidase activity 13. Our results indicate that both of ACF and BCAC possess decreased activity of this enzyme although β-catenin accumulation is present only at BCAC 12. BCAC have accumulation of β-catenin protein in the cytoplasm as well as in the nuclei 11,12 (Fig. 1). In our previous study, β-catenin gene mutations were found in 10 out 15 BCAC, although such mutation was recognized only in 3 of 15 ACF. Mutation of β-catenin gene in BCAC is usually recognized in codons 28, 30, 32, 34, and 41 11. Very recently, we conducted a study to compare types of the β-
catenin and k-ras mutations of BCAC with those of colon
tumors. Mutations in the exon 3 of β-catenin gene were
respectively detected in 39.3% of BCAC and 56.8% of colon
cancers. Remarkably, all β-catenin mutations recognized in
the colon tumors converged at codons encoding functionally
important residues that may directly mediate β-catenin
degradation, whereas mutations in the early appearing
lesions laid scattered in the exon 3 of the gene. In this study,
frequency of k-ras mutations was rather higher than in colon
cancers (unpublished results). Recently, target genes of the
β-catenin-Tcf pathway were determined to be growth-
promoting genes, such as c-myc and cyclin D1. It is also
known that β-catenin levels are regulated by degradation of
the protein via ubiquitin-protease pathway, and intact APC
and AXIN cooperate with GSK-3β to regulate the
degradation. Accordingly, our recent evidences suggest
that broad spectrum of mutations are selected during the
malignant transformation of the colon, and the main
selective factor will be an activation of the β-catenin
down-regulating function. It is also implied that activation of β-
catenin signaling pathway is not only an initiating event, but
also plays a pivotal role in the promotion stage of colorectal
carcinogenesis.

Modification of Expression of BCAC

Suppression of occurrence and advancement of
premalignant lesions is important for cancer prevention.
Effects of a selective cyclooxygenase-2 inhibitor, celecoxib
which chemopreventive effect on the large bowel
carcinogenesis has been confirmed in animal models18,19, on
the development of BCAC in comparison with those of ACF
was examined by us19. In this study, expression of BCAC
was suppressed by exposure of celecoxib, and the
suppression at BCAC was much more stronger than at ACF.
Similarly, crypt multiplicity of BCAC was decreased by
celecoxib and the decrease was stronger than at ACF.
Numbers of silver stained nucleolar organizer regions /
nucleus in BCAC were also decreased by celecoxib20. These
data represent additional evidences that BCAC are
premalignant lesions of colon cancer and suggest that
chemopreventive effect of celecoxib is related to the
decrease of expression of premalignant lesions as well as
modulation of cell proliferation in the early appearing
lesions.

It is considered that tumor promoters which enhance
development of neoplasms also enhance the development of
early appearing precancerous lesions in the target organs.
Magnussen and Bird\textsuperscript{21}, however, reported that cholic acid, a tumor promoter for colon cancers, did not enhance the occurrence of ACF but suppressed the expression of the lesions. Modulating effect of this secondary bile acid on the expression of BCAC in comparison with ACF was investigated by us. In this study, expression of ACF was markedly inhibited by exposure of cholic acid whereas that of BCAC was slightly promoted. Furthermore, number of crypts / focus and diameter of ACF was decreased by cholic acid, yet the number and size of BCAC were increased by exposure of cholic acid whereas that of BCAC was slightly promoted. These results indicate a clear difference on the biological properties of both lesions and again support that BCAC are probably the genuine premalignant lesions for colorectal cancers.

### Induction of Cellular Apoptosis in BCAC and Its Significance

It seems to be true that there are multiple mechanisms for the actions of chemopreventive agents. Induction of cellular apoptosis is regarded as one of important mode of actions of them. This biological action is considered to be particularly important for the non-steroidal anti-inflammatory drugs (NSAIDs) among a variety of chemopreventive compounds. In fact, it is known that some NSAIDs induce cellular apoptosis\textsuperscript{23}. However, such evidences of NSAIDs have been obtained mostly \textit{in vitro} studies. Thus, it is noteworthy to know in \textit{in vivo} studies whether such agents induce apoptosis in the premalignant lesions or not. A NSAID (sulindac) was investigated for the potential to generate apoptosis in the precancerous lesions (BCAC and ACF) for colorectal cancers by us. Exposure of sulindac in diet (200 or 400 ppm) dose-dependently increased the apoptotic index (TUNEL staining was used as a biomarker for the apoptosis) in BCAC. However, no significant increase of the index was confirmed in the case of ACF (Table 1). In this study, the degree of sulindac-induced reduction of cell proliferation in BCAC exceeded that seen in ACF\textsuperscript{24}.

### Comments

Data provided by us suggest that BCAC are a possibly direct precursor for colorectal cancers. We would like emphasis that BCAC are promising biomarker for the risk assessment of environmental carcinogens and also for screening of chemopreventive agents, although the bio-assay for BCAC is technically more difficult than for ACF. The finding of BCAC will provide an important clue for the understanding of premalignant lesions for the large bowel cancers and the mechanisms of intestinal carcinogenesis. Our recent results from the comparative analysis on BCAC and colon cancers in rats suggest that β-catenin mutation is selected during the colon carcinogenesis. Recently, Paulsen \textit{et al.}\textsuperscript{25} reported the absence of “classical” ACF in the colon of Min/+ mice. Instead, they identified the flat dysplastic lesions, which were denoted as ACFMin. Such lesions with flat structures are hidden in the surrounding mucosa. These evidences are consistent with the results on BCAC in our studies. Although intestinal lesions like BCAC have not yet been clarified in humans, it is likely that similar types of mutations may occur in the early appearing lesions and tumors in the colons of humans.

### Table 1. Apoptotic Index of Normal Crypts, ACF and BCAC

<table>
<thead>
<tr>
<th>Groups (Treatment)</th>
<th>Normal crypts</th>
<th>ACF</th>
<th>BCAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>AOM + basal diet</td>
<td>0.11 ± 0.10\textsuperscript{a} (16)</td>
<td>0.17 ± 0.60 (223)</td>
<td>0.15 ± 0.55 (56)</td>
</tr>
<tr>
<td>AOM→sulindac (200 ppm)</td>
<td>0.15 ± 0.12 (16)</td>
<td>0.20 ± 0.72 (212)</td>
<td>0.99 ± 1.43 (56)</td>
</tr>
<tr>
<td>AOM→sulindac (400 ppm)</td>
<td>0.17 ± 0.10 (16)</td>
<td>0.25 ± 0.66 (166)</td>
<td>1.45 ± 2.71 (69)</td>
</tr>
</tbody>
</table>

Numbers in parenthese are numbers of examined lesions. \textsuperscript{a}: Mean ± SD.

\textsuperscript{b}: Significantly different from the group with AOM + basal diet (P<0.0003).

### References


16. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, and Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3\(\beta\)-and $\beta$-catenin and promotes GSK-3\(\beta\)-dependent phosphorylation of $\beta$-catenin. EMBO J 1998; 17: 1371–1384.


